Sule-Suso, J, Watson, NA, van Pittius, DG and Jegannathen, A (2019) Striking lung cancer response to self-administration of cannabidiol: a case report and literature review. SAGE Open Medical Case Reports, 7. ISSN 2050-313X

[thumbnail of Sulé-Suso.docx] Text
Sulé-Suso.docx - Accepted Version
Available under License Creative Commons Attribution Non-commercial.

Download (8MB)


In spite of new drugs, lung cancer is associated with a very poor prognosis. Whilst targeted therapies are improving outcomes, it is not uncommon for many patients to have only a partial response, and relapse during follow up. Thus, new drugs or re-evaluation of existing therapies used to treat other non-malignant diseases (drug repurposing) are still needed. While this research both in vitro and in vivo is being carried out, it is important to be attentive to patients where the disease responds to treatments not considered standard in clinical practice. We report here a patient with adenocarcinoma of the lung who, after declining chemotherapy and radiotherapy, presented with tumour response following self-administration of cannabidiol, a non-psychoactive compound present in cannabis sativa. Prior work has shown that cannabidiol may have anti-neoplastic properties and enhance the immune response to cancer. The data presented here indicates that cannabidiol might have led to a striking response in a patient with lung cancer.

Item Type: Article
Additional Information: This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Sage Publications at - please refer to any applicable terms of use of the publisher.
Uncontrolled Keywords: lung cancer, cannabinoid, cannabidiol
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions: Faculty of Medicine and Health Sciences > Institute for Science and Technology in Medicine
Depositing User: Symplectic
Date Deposited: 12 Feb 2019 15:48
Last Modified: 29 Mar 2019 11:37

Actions (login required)

View Item
View Item